Standards & guidance

Filter Standards and Guidance documents

Page 1 of 10

FSRH/BASHH Standards for Online and Remote Providers of Sexual and Reproductive Health Services - January 2019

24 January 2019

The rapid expansion in the number of providers of online Sexual and Reproductive Health/Sexual and Reproductive Healthcare (SH/SRH) services has enabled and empowered users to access their healthcare in more ways than through a face-to-face consultation with the health care professional. The FSRH and BASHH support these innovations and recognise that these services have enormous potential. They are seeking, however, key assurances in the standards of care and quality of services provided.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Clinical Guideline: Intrauterine contraception (March 2023, Amended July 2023)

17 July 2023

The guideline provides evidence-based recommendations and good practice points to enable clinicians to support individuals to make informed decisions about choosing and using IUC. It includes information on assessing suitability of IUC use for contraception, the risks and benefits of IUC and guidance for IUC procedures, complications and follow-up. Published March 2023. Please read this guidance document in conjunction with any relevant clinical statements for this topic: FSRH CEU Statement: Mirena 8 years contraception (Jan 2024) FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023) FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023) FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018) FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018) FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017) FSRH CEU Statement: Response to Study: Intrauterine Contraception Use and Cervical Cancer Risk (January 2018) FSRH CEU Statement: Contraception and Weight Gain (August 2019) The digital version can be accessed from the BMJ SRH website:  FSRH Guideline (March 2023) Intrauterine contraception BMJ Sexual & Reproductive Health 2023;49:1-142.  

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Guidance: Combined Hormonal Contraception Quick Reference Summary (January 2019, updated October 2023)

15 June 2023

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on combined hormonal contraception (CHC). Please refer to the full 2018 FSRH CHC Clinical Guideline for further information and evidence for this advice. This document is written for FSRH members and requires you to log in to access it. 

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended October 2023)

13 July 2023

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of combined hormonal contraceptives (i.e. the combined oral contraceptive pill, transdermal patch and combined vaginal ring) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. Please read this guidance document in conjunction with any relevant clinical statements for this topic: FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023) FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023) FSRH CEU Statement: New manufacturer/MHRA advice regarding nomegestrol acetate – how does this affect prescribing of Zoely®? (April 2023) FSRH CEU Statement : New advice from the MHRA regarding cyproterone acetate: how does this affect prescribing of Co-cyprindiol/Dianette® for acne/hirsutism? July 2020 FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018) FSRH CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014) FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017) FSRH CEU Statement: Contraception and Weight Gain (August 2019) FSRH CEU Statement: Response to new reports of link between COC and Glaucoma (November 2013) The digital version can be accessed from the BMJ SRH website:  FSRH Guideline (January 2019, amended November 2020) Combined Hormonal Contraception. BMJ Sexual & Reproductive Health 2019; 45:Suppl 1.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Response to new study by Meaidi et al (September 2023)

07 September 2023

This FSRH Statement responses to a recently published study by Meaidi et al. published on 06/09/2023 which used data from nationwide Danish databases to compare risk of first VTE events during use of hormonal contraception (HC) with that during concomitant use of HC and the non-steroidal anti-inflammatory drugs (NSAIDs) ibuprofen, diclofenac or naproxen.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Clinical Guideline: Progestogen-only Implant (February 2021, Amended July 2023)

17 July 2023

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. Please read this guidance document in conjunction with any relevant clinical statements for this topic: FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023) FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023) FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018) FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018) FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017) FSRH CEU Statement: Contraception and Weight Gain (August 2019) The digital version can be accessed from the BMJ SRH website:  FSRH Guideline (February 2021) Progestogen-only Implant. BMJ Sexual & Reproductive Health 2021; 47:Suppl 1.  

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Clinical Guideline: Progestogen-only Injectable (December 2014, Amended July 2023)

17 July 2023

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. Please read this guidance document in conjunction with any relevant clinical statements for this topic: FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023) FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023) FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018) FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018) FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017) FSRH CEU Statement: Contraception and Weight Gain (August 2019)

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Clinical Guideline: Progestogen-only Pills (August 2022, Amended July 2023)

17 July 2023

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any health care professional or health service providing contraceptive care in the UK. Please read this guidance document in conjunction with any relevant clinical statements for this topic: FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023) FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023) FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018) FSRH CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014) FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018) FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017) FSRH CEU Statement: Contraception and Weight Gain (August 2019) Also available in digital format on the BMJ website: FSRH Guideline (August 2022) Progestogen-only Pills. BMJ Sexual & Reproductive Health 2022; 48:Suppl 1 .

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date